Sumitomo Mitsui Trust Holdings Inc. Buys 3,267 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sumitomo Mitsui Trust Holdings Inc. lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 210,028 shares of the company’s stock after acquiring an additional 3,267 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.25% of IDEXX Laboratories worth $113,400,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Brevan Howard Capital Management LP bought a new position in shares of IDEXX Laboratories in the fourth quarter worth $3,183,000. Assenagon Asset Management S.A. boosted its holdings in shares of IDEXX Laboratories by 25.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after acquiring an additional 8,831 shares during the period. Carderock Capital Management Inc. boosted its holdings in shares of IDEXX Laboratories by 35.7% in the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock worth $9,112,000 after acquiring an additional 4,315 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in shares of IDEXX Laboratories by 9.4% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 42,045 shares of the company’s stock worth $23,307,000 after acquiring an additional 3,627 shares during the period. Finally, Meyer Handelman Co. bought a new stake in IDEXX Laboratories during the first quarter valued at $2,155,000. 87.84% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the transaction, the director now owns 161 shares in the company, valued at approximately $87,068.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Up 0.1 %

Shares of NASDAQ:IDXX opened at $477.49 on Thursday. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The company has a market cap of $39.44 billion, a PE ratio of 46.22, a P/E/G ratio of 3.89 and a beta of 1.32. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. The stock’s 50-day moving average is $501.19 and its 200 day moving average is $525.60.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The company had revenue of $964.10 million for the quarter, compared to the consensus estimate of $965.43 million. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on IDXX shares. Morgan Stanley dropped their price objective on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. Barclays dropped their price target on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, June 14th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Finally, Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.